HAIRY CELL LEUKEMIA
Clinical trials for HAIRY CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new HAIRY CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for HAIRY CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets rare blood cancer in early trial
Disease control OngoingThis early-phase study tests the safety of combining two drugs, moxetumomab pasudotox and rituximab, for people with hairy cell leukemia that has not responded to standard treatment. About 18 adults will receive up to 8 cycles of the drugs through an IV. The main goal is to find …
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Targeted drug ibrutinib shows promise against rare leukemia
Disease control OngoingThis phase 2 trial tests the drug ibrutinib in 44 people with hairy cell leukemia that has come back after treatment. Ibrutinib works by blocking a protein that helps cancer cells grow. The main goal is to see how many patients achieve remission within 32 weeks.
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for Tough-to-Treat hairy cell leukemia
Disease control OngoingThis phase 2 trial tests whether a combination of two oral drugs, encorafenib and binimetinib, works better than the current drug vemurafenib for people with hairy cell leukemia that has a BRAF mutation and has either not responded to treatment or returned. About 28 adults will t…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered t cells take on tough leukemia and lymphoma
Disease control OngoingThis early-phase trial tests a two-part treatment for people with relapsed or chemotherapy-resistant B-cell leukemia or lymphoma. First, patients receive a chemotherapy drug (cyclophosphamide) to help prepare the body. Then, they get an infusion of their own T cells that have bee…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo therapy shows promise for rare leukemia patients
Disease control OngoingThis study tests a combination of two drugs, vemurafenib (a pill) and obinutuzumab (an infusion), in 30 people with previously untreated hairy cell leukemia. The goal is to see how many patients achieve a complete response, meaning no signs of cancer after treatment. Participants…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC